Scotiabank Begins Coverage on Gain Therapeutics (NASDAQ:GANX)

Stock analysts at Scotiabank began coverage on shares of Gain Therapeutics (NASDAQ:GANX) in a research note issued to investors on Friday, Marketbeat reports. The firm set a “sector outperform” rating and a $12.00 price target on the stock.

Other equities research analysts have also recently issued research reports about the stock. HC Wainwright restated a “buy” rating and issued a $8.00 target price on shares of Gain Therapeutics in a report on Monday, November 25th. Roth Mkm restated a “buy” rating and issued a $7.00 price target on shares of Gain Therapeutics in a research note on Tuesday, December 24th. Finally, Roth Capital raised Gain Therapeutics to a “strong-buy” rating in a report on Thursday, December 5th. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Gain Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $8.20.

Gain Therapeutics Price Performance

GANX opened at $1.88 on Friday. The company’s 50-day simple moving average is $2.25 and its two-hundred day simple moving average is $1.96. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.99 and a current ratio of 2.99. The stock has a market capitalization of $49.87 million, a P/E ratio of -1.71 and a beta of 0.14. Gain Therapeutics has a 52-week low of $0.89 and a 52-week high of $4.80.

Hedge Funds Weigh In On Gain Therapeutics

A number of institutional investors have recently bought and sold shares of GANX. Geode Capital Management LLC grew its holdings in Gain Therapeutics by 48.0% during the third quarter. Geode Capital Management LLC now owns 271,972 shares of the company’s stock valued at $484,000 after purchasing an additional 88,236 shares during the period. Benedict Financial Advisors Inc. purchased a new position in shares of Gain Therapeutics during the 4th quarter valued at about $35,000. Sprott Inc. bought a new position in shares of Gain Therapeutics during the 4th quarter valued at approximately $30,000. Jones Financial Companies Lllp increased its holdings in Gain Therapeutics by 83.6% in the 4th quarter. Jones Financial Companies Lllp now owns 98,250 shares of the company’s stock worth $212,000 after acquiring an additional 44,750 shares in the last quarter. Finally, Marshall Wace LLP bought a new stake in Gain Therapeutics during the 4th quarter worth approximately $198,000. 11.97% of the stock is owned by institutional investors.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.